Investigational drug · Phase 2
BI 1584862
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Geographic Atrophy.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "BI 1584862"
First trial start
2025
Jan 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 1584862", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy
Approved drugs for the same conditions: Geographic atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 1584862" as an intervention, largest first.
- A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06769048 · 150 participants · Start Jan 31, 2025 · Primary completion Dec 22, 2026
Drug: Placebo-matching BI 1584862; BI 1584862 · For: Geographic Atrophy
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 44 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05520827 · 77 participants · Start Sep 29, 2022 · Primary completion Mar 6, 2023
Drug: BI 1584862; Placebo · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT06006598 · 50 participants · Start Aug 28, 2023 · Primary completion May 5, 2024
Drug: BI 1584862; Placebo matching BI 1584862 and 1 more · For: Healthy
Sites: Berlin, Germany
- A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver ProblemsCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06957756 · 43 participants · Start Aug 6, 2025 · Primary completion May 21, 2026
Drug: BI 1584862 · For: Hepatic Insufficiency
Sites: Chandler, Arizona; Orlando, Florida; San Antonio, Texas
Boehringer IngelheimBoehringer Ingelheim
NCT06148948 · 32 participants · Start Dec 25, 2023 · Primary completion May 21, 2024
Drug: BI 1584862; Placebo · For: Healthy
Sites: Tokyo, Sumida-ku, Japan
- A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the BloodCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT07211425 · 14 participants · Start Oct 8, 2025 · Primary completion Jan 21, 2026
Drug: BI 3031185; Itraconazole · For: Healthy
Sites: Biberach, Germany
- A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the BloodCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06041438 · 14 participants · Start Sep 29, 2023 · Primary completion Nov 10, 2023
Drug: BI 1584862; Itraconazole · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT07336758 · 8 participants · Start Jan 22, 2026 · Primary completion Mar 4, 2026
Drug: [13C]-labeled BI 1584862; Unlabeled BI 1584862 mixed with [14C]-labeled BI 1584862 · For: Healthy
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Geographic Atrophy
- TinlarebantLBS-008Phase 33 trials
Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy
- JNJ-81201887AAVCAGsCD59Phase 32 trials
Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration
- VonaprumentANX007Phase 32 trials
Annexon, Inc. · Geographic Atrophy
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- STL303Phase 22 trials
Sitala Bio LTD · IgAN, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- BI 771716Phase 21 trial
Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy
- BRX011Phase 21 trial
Biojiva LLC · Geographic Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.